scholarly journals Effects of Mimosine, a Potential Chemical Defleecing Agent, on Wool Growth and the Skin of Sheep

1975 ◽  
Vol 28 (1) ◽  
pp. 69 ◽  
Author(s):  
PJ Reis ◽  
DA Tunks ◽  
RE Chapman
Keyword(s):  
Intravenous Infusion ◽  
Intraperitoneal Injection ◽  
Continuous Intravenous Infusion ◽  
Merino Sheep ◽  
Wool Growth

Twenty-two Merino sheep were dosed with various amounts of L-mimosine, given either as an intravenous or an intraperitoneal injection, or as a continuous intravenous infusion for periods of 1-4 days.

scholarly journals Effect of Intravenously Infused Dexamethasone on Collagen Metabolism in Skin of Merino Sheep

1979 ◽  
Vol 32 (6) ◽  
pp. 561
Author(s):  
Z Leish ◽  
BA Panaretto
Keyword(s):  
Body Weight ◽  
Intravenous Infusion ◽  
Collagen Metabolism ◽  
Merino Sheep ◽  
Wool Growth

The effects of an 8-day intravenous infusion of dexamethasone (7�6 mg kg-o.75 body weight) on collagen biosynthes's and wool growth in skin were examined in four Merino wethers.

scholarly journals Effects of Intravenous Infusion of Mimosine on Wool Growth of Merino Sheep

1975 ◽  
Vol 28 (6) ◽  
pp. 483 ◽  
Author(s):  
PJ Reis
Keyword(s):  
Amino Acids ◽  
Intravenous Infusion ◽  
Merino Sheep ◽  
Wool Growth ◽  
Intravenous Infusions

Merino sheep were given continuous intravenous infusions of L-mimosine for periods of It, 2 or 21 days; efficacy as a defleecing procedure and effects on subsequent wool growth were measured. In addition, the amino acids tyrosine, phenylalanine and cystine were investigated as antagonists to the effects of mimosine.

The influence of nutrition on the effectiveness of mimosine for defleecing sheep

1978 ◽  
Vol 29 (5) ◽  
pp. 1057 ◽  
Author(s):  
PJ Reis ◽  
DA Tunks
Keyword(s):  
Amino Acids ◽  
Growth Rate ◽  
Intravenous Infusion ◽  
Continuous Intravenous Infusion ◽  
High Intake ◽  
Wool Growth ◽  
Abomasal Infusion ◽  
High Feed ◽  
Standard Rate ◽  
Small Intestines

The effectiveness of mimosine as a chemical defleecing agent was assessed in adult sheep that were subjected to a variety of nutritional treatments prior to administration of mimosine, and in lambs receiving relatively high feed intakes. Mimosine was given as a continuous intravenous infusion over a period of 2 days. Sheep receiving 600 g of a roughage-based diet per day were consistently defleeced following an infusion of mimosine at the rate of 80 mg/kg/day (designated the standard infusion). The prior feeding of a reduced intake of this diet (300 g/day) did not alter the amount of mimosine required to defleece sheep. Likewise, the prior abomasal infusion of an imbalanced mixture of amino acids, which depressed the wool growth rate, did not allow defleecing with a reduced amount of mimosine. A 4-day fast, commenced 3 days before the start of mimosine infusion, approximately halved the amount of mimosine required to defleece sheep. The provision of a high intake of energy, together with large amounts of amino acids available for absorption from the small intestines (supplied by casein), for at least 1 week prior to mimosine infusion, completely prevented defleecing with the standard infusion of mimosine. The effects of these nutritional treatments could be obviated by a 4-day fast as described above. Also, increasing the rate of infusion of mimosine to 120 mg/kg/day largely overcame the effects of previous high nutrition. Relatively greater amounts of mimosine were required to defleece lambs than adults. The concentration of mimosine in plasma was related to the rate of infusion of mimosine. However, fasting and a low dietary intake tended to enhance the concentration of mimosine in plasma for a given rate of infusion. Infusion of mimosine at the standard rate resulted in plasma mimosine concentrations of the order of 100 µmoles/l, but this concentration did not ensure that defleecing would be possible.

Efficacy of octreotide (Octrade) for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

2020 ◽  
Vol 1 (30) ◽  
pp. 30-36
Author(s):  
E. A. Krylova ◽  
D. V. Aleinik
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Intravenous Infusion ◽  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Continuous Intravenous Infusion ◽  
Endoscopic Retrograde ◽  
Pancreatic Enzyme Secretion

The article presents the results of a study of the effectiveness of the use of an inhibitor of pancreatic enzyme secretion of octreotide (Octrade) for the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). It was shown that the administration of Octrade at a dose of 0.3 mg in 500 ml of 0.9 % NaCl by continuous intravenous infusion for 7 hours and then 0.1 mg of Octrade subcutaneously at 6 and 12 hours after the end of intravenous infusion significantly reduced the frequency of pancreatitis (4.0 % and 22.2 %; p < 0.05) and hyperamylasemia (8.0 % and 25.9 %; p < 0.05) after ERCP. It is concluded that Octrade is effective in preventing the development of pancreatitis and hyperamilasemia after ERCP.

scholarly journals Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies

2021 ◽  
Vol 9 (4) ◽  
pp. e002193
Author(s):  
Sigrid P Dubois ◽  
Milos D Miljkovic ◽  
Thomas A Fleisher ◽  
Stefania Pittaluga ◽  
Jennifer Hsu-Albert ◽  
...  
Keyword(s):  
Nk Cells ◽  
Natural Killer ◽  
Intravenous Infusion ◽  
Nk Cell ◽  
Continuous Intravenous Infusion ◽  
Dose Escalation Study ◽  
Link Type ◽  
Best Response ◽  
Antitumor Antibodies ◽  
Interleukin 15

BackgroundFull application of cytokines as oncoimmunotherapeutics requires identification of optimal regimens. Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions. Subcutaneous injection and continuous intravenous infusion for 10 days (CIV-10) provided rhIL-15 with less toxicity with CIV-10 giving the best increases in CD8+ lymphocytes and natural killer (NK) cells. To ease rhIL-15 administration, we shortened time of infusion. Treatment with rhIL-15 at a dose of 3–5 µg/kg as a 5-day continuous intravenous infusion (CIV-5) had no dose-limiting toxicities while effector cell stimulation was comparable to the CIV-10 regimen.MethodsEleven patients with metastatic cancers were treated with rhIL-15 CIV-5, 3 µg (n=4), 4 µg (n=3), and 5 µg/kg/day (n=4) in a phase I dose-escalation study (April 6, 2012).ResultsImpressive expansions of NK cells were seen at all dose levels (mean 34-fold), including CD56bright NK cells (mean 144-fold for 4 µg/kg), as well as an increase in CD8+ T cells (mean 3.38-fold). At 5 µg/kg/day, there were no dose-limiting toxicities but pulmonary capillary leak and slower patient recovery. This led to our choice of the 4 µg/kg as CIV-5 dose for further testing. Cytolytic capacity of CD56bright and CD56dim NK cells was increased by interleukin-15 assayed by antibody-dependent cellular cytotoxicity (ADCC), natural cytotoxicity and natural killer group 2D-mediated cytotoxicity. The best response was stable disease.ConclusionsIL-15 administered as CIV-5 substantially expanded NK cells with increased cytotoxic functions. Tumor-targeting monoclonal antibodies dependent on ADCC as their mechanism of action including alemtuzumab, obinutuzumab, avelumab, and mogamulizumab could benefit from those NK cell expansions and provide a promising therapeutic strategy.Trial registration numbersNCT01572493, NCT03759184, NCT03905135, NCT04185220 and NCT02689453.

Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia

2005 ◽  
Vol 23 (30) ◽  
pp. 7697-7702 ◽  
Author(s):  
Susan M. O'Brien ◽  
Charles C. Cunningham ◽  
Anatoliy K. Golenkov ◽  
Anna G. Turkina ◽  
Steven C. Novick ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Phase I ◽  
Phase Ii ◽  
Intravenous Infusion ◽  
Single Agent ◽  
Plasma Concentrations ◽  
Parent Drug ◽  
Lymphocytic Leukemia ◽  
Complete Disappearance ◽  
Continuous Intravenous Infusion

Purpose To determine the maximum-tolerated dose (MTD), efficacy, safety, and pharmacokinetics of oblimersen sodium in patients with advanced chronic lymphocytic leukemia (CLL). Patients and Methods Eligible patients had relapsed or refractory CLL after treatment with fludarabine. Oblimersen was administered at doses ranging from 3 to 7 mg/kg/d as a 5-day continuous intravenous infusion in cycle 1 and as a 7-day continuous intravenous infusion in subsequent cycles every 3 weeks in stable or responding patients. Results Forty patients were enrolled and treated (14 patients in phase I and 26 patients in phase II). Dose-limiting reactions in phase I included hypotension and fever, and the MTD for phase II dosing was established at 3 mg/kg/d. Two (8%) of 26 assessable patients achieved a partial response. Other evidence of antitumor activity included ≥ 50% reduction in splenomegaly (seven of 17 patients; 41%), complete disappearance of hepatomegaly (two of seven patients; 29%), ≥ 50% reduction of lymphadenopathy (seven of 22 patients; 32%), and ≥ 50% reduction in circulating lymphocyte counts (11 of 22 patients; 50%). Adverse events included transient hypotension, fever, fatigue, night sweats, diarrhea, nausea, vomiting, hypokalemia, and cough. Plasma concentrations of oblimersen (parent drug) and its major metabolites were variable. Renal clearance represented only a small portion of total parent drug clearance. Conclusion Dosing with oblimersen sodium in patients with CLL is limited by development of a cytokine release syndrome that is characterized by fever, hypotension, and back pain. Oblimersen sodium has modest single-agent activity in heavily pretreated patients with advanced CLL, and further evaluation of its activity in combination with cytotoxic drugs is warranted.

PROLONGED INTRAVENOUS INFUSION OF LABELLED IODOCOMPOUNDS IN THE RAT: [125I]IODIDE METABOLISM AND EFFECTS OF MODERATE DIETARY IODINE DEFICIENCY

1979 ◽  
Vol 82 (2) ◽  
pp. 227-234 ◽  
Author(s):  
VIPA BOONNAMSIRI ◽  
J. C. KERMODE ◽  
B. D. THOMPSON
Keyword(s):  
Skeletal Muscle ◽  
Iodine Deficiency ◽  
Intravenous Infusion ◽  
Structure And Function ◽  
Continuous Intravenous Infusion ◽  
Close Approximation ◽  
Faecal Excretion ◽  
And Function ◽  
Layer Chromatography ◽  
Secretion Rates

SUMMARY Radio-iodide was administered by prolonged continuous intravenous infusion to rats maintained under iodine-replete conditions and in moderate iodine deficiency. A close approximation to equilibrium labelling was thereby achieved. Labelled iodocompounds extracted from various tissues were analysed by thin-layer chromatography. Moderate iodine deficiency resulted in a slight increase in the ratio of mono-iodotyrosine to di-iodotyrosine in the thyroid. No change in the ratio of tri-iodothyronine (T3) to thyroxine (T4) was found in thyroid, plasma or skeletal muscle. Faecal excretion of T3 declined appreciably relative to that of T4. Under iodine-replete conditions the ratio of thyroidal secretion rates of T3 and T4 was estimated to be more than three times higher than the ratio of these iodocompounds within the thyroid. Heterogeneity of thyroglobulin structure and function may explain these observations.

Continuous intravenous infusion fentanyl for sedation and analgesia of the multiple trauma patient

1991 ◽  
Vol 20 (8) ◽  
pp. 913-915 ◽  
Author(s):  
Mark Walsh ◽  
Greg A Smith ◽  
Robert A Yount ◽  
Frederick J Ferlic ◽  
Martin F Wieschhaus
Keyword(s):  
Trauma Patient ◽  
Multiple Trauma ◽  
Intravenous Infusion ◽  
Continuous Intravenous Infusion ◽  
Multiple Trauma Patient ◽  
Sedation And Analgesia

scholarly journals Ifosfamide treatment as a 10-day continuous intravenous infusion

1995 ◽  
Vol 121 (8) ◽  
pp. 492-492
Author(s):  
H. J. Keizer ◽  
J. Ouwerkerk ◽  
K. Welvaart ◽  
C. J. H. van der Velde ◽  
F. J. Cleton
Keyword(s):  
Intravenous Infusion ◽  
Continuous Intravenous Infusion

scholarly journals Ceftazidime in Acute Myeloid Leukemia Patients with Febrile Neutropenia: Helpfulness of Continuous Intravenous Infusion in Maximizing Pharmacodynamic Exposure

2005 ◽  
Vol 49 (8) ◽  
pp. 3550-3553 ◽  
Author(s):  
Federico Pea ◽  
Pierluigi Viale ◽  
Daniela Damiani ◽  
Federica Pavan ◽  
Francesco Cristini ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Acute Myeloid Leukemia ◽  
Steady State ◽  
Intravenous Infusion ◽  
Myeloid Leukemia ◽  
Continuous Intravenous Infusion ◽  
Pharmacokinetic Variability ◽  
Pharmacodynamic Profile ◽  
Neutropenic Patients ◽  
Acute Myeloid

ABSTRACT The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period.

Sign in / Sign up

Export Citation Format

Share Document